- Home
- ROIV vs LII Comparison
ROIV vs LII Comparison
Compare ROIV & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | LII |
|---|---|---|
| Founded | 2014 | 1895 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 17.2B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ROIV | LII |
|---|---|---|
| Price | $30.28 | $509.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 13 |
| Target Price | $28.94 | ★ $566.58 |
| AVG Volume (30 Days) | ★ 5.9M | 336.6K |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | N/A | ★ 1.11 |
| EPS | N/A | ★ 3.35 |
| Revenue | $8,260,000.00 | ★ $5,195,300,000.00 |
| Revenue This Year | N/A | $6.85 |
| Revenue Next Year | $744.61 | $5.76 |
| P/E Ratio | ★ N/A | $154.21 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.71 | $434.06 |
| 52 Week High | $32.79 | $689.44 |
Technical Indicators
Market Signals| Indicator | ROIV | LII |
|---|---|---|
| Relative Strength Index (RSI) | 56.52 | 51.00 |
| Support Level | $27.44 | $478.75 |
| Resistance Level | $32.79 | $536.54 |
| Average True Range (ATR) | 0.87 | 19.28 |
| MACD | 0.01 | 0.75 |
| Stochastic Oscillator | 86.99 | 47.18 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About LII Lennox International Inc.
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounts for 67% of sales and commercial HVAC (building climate solutions) accounts for the remaining 33% of sales. Lennox's commercial exposure is what its peers refer to as residential and light commercial, and lacks the scale and complexity of what is referred to as an applied solution. The company goes to market with multiple brands, but Lennox is its flagship HVAC brand.